Hepatitis D virus infection
T Asselah, M Rizzetto - New England Journal of Medicine, 2023 - Mass Medical Soc
Hepatitis D Virus Infection | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV …
Representatives from academia, industry, regulatory agencies, and patient advocacy groups
convened under the American Association for the Study of Liver Diseases (AASLD) and the …
convened under the American Association for the Study of Liver Diseases (AASLD) and the …
A phase 3, randomized trial of bulevirtide in chronic hepatitis D
Background Coinfection with hepatitis D virus (HDV) accelerates the progression of liver
disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into …
disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into …
EASL Clinical Practice Guidelines on hepatitis delta virus
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B virus to complete its
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
[HTML][HTML] Treating hepatitis D with bulevirtide–Real-world experience from 114 patients
C Dietz-Fricke, F Tacke, C Zöllner, M Demir… - Jhep Reports, 2023 - Elsevier
Background & Aims Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen.
In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most …
In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most …
[HTML][HTML] Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
P Lampertico, E Degasperi, L Sandmann… - JHEP Reports, 2023 - Elsevier
Chronic infection with hepatitis Delta virus (HDV) affects between 12-20 million people
worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver …
worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver …
New perspectives on development of curative strategies for chronic hepatitis B
A functional cure of chronic hepatitis B defined as sustained hepatitis B surface antigen loss
after finite course of therapy is rarely achieved with current therapy but is the goal of novel …
after finite course of therapy is rarely achieved with current therapy but is the goal of novel …
Bulevirtide in the treatment of hepatitis delta: drug discovery, clinical development and place in therapy
It has been ten years since the identification of NTCP as the cell surface receptor for HBV
and HDV entry into hepatocytes. The search for molecules interfering with the binding of …
and HDV entry into hepatocytes. The search for molecules interfering with the binding of …
HDV RNA Assays: Performance characteristics, clinical utility and challenges
H Wedemeyer, M Leus, TR Battersby, J Glenn… - Hepatology, 2023 - journals.lww.com
Co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV) results in hepatitis D,
the most severe form of chronic viral hepatitis, frequently leading to liver decompensation …
the most severe form of chronic viral hepatitis, frequently leading to liver decompensation …